FBR Capital Resumes Coverage with a Buy Rating on Omnicell

By George MacDonald

In a report released today, Steven Halper from FBR resumed coverage with a Buy rating on Omnicell (NASDAQ: OMCL) and a price target of $33. The company opened today at $32.31.

Omnicell has an analyst consensus of Moderate Buy, with a price target consensus of $31.50.

Based on Omnicell`s latest earnings report from June 30, the company posted quarterly revenue of $105.1M and quarterly net profit of $7.79M. In comparison, last year the company earned revenue of $94.04M and had a net profit of $7.76M.

According to TipRanks.com, Halper is a 4-star analyst with an average return of 19.6% and a 93.8% success rate. Halper covers the Technology sector, focusing on stocks such as Quality Systems, Athenahealth, and Cerner Corp.

Omnicell, Inc., provides automation & business information solutions to update medication administration process & manage costly medical supplies for operational efficiency & patient safety. Its operating business segments are acute care & non-acute care.